Supplementary Table 1.
Available data at baseline and 6 months of follow-up in infliximab and etanercept treated SpA patients shown as percentages

	Infliximab N=1319		Etanercept N=1015	
	INF (N=320)	CT-P13 (N=999)	ETN (N=493)	SB4 (N=522)
Baseline				
Age, years	100%	100%	100%	100%
Disease duration, years	89%	55%	77%	88%
Sex	100%	100%	100%	100%
AS, nrax-SpA or uSpA	100%	100%	100%	100%
Psoriasis*	98%	83%	97%	97%
Inflammatory bowel disease*	98%	83%	97%	97%
CRP	61%	70%	62%	60%
Patient global	51%	66%	54%	57%
Patient pain	52%	66%	57%	57%
ASDAS	37%	55%	35%	39%
BASDAI, mm	45%	60%	43%	46%
BASFI, mm	40%	51%	39%	40%
Concomitant csDMARD**	68%	78%	69%	72%
Reason for discontinuation	100%	100%	100%	100%
6 months follow-up				
CRP	69%	80%	71%	61%
Patient global	65%	83%	62%	62%
Patient pain	66%	81%	65%	62%
ASDAS	52%	70%	41%	48%
BASDAI	55%	78%	48%	53%
Available at both baseline and 6 months follow-up				
CRP	45%	59%	44%	35%
Patient global	36%	60%	39%	34%
Patient pain	36%	60%	42%	34%
ASDAS	23%	47%	21%	23%
BASDAI	29%	55%	28%	25%

Abbreviations: AS: ankylosing spondylitis; ASDAS= ankylosing spondylitis disease activity score; BASDAI: Bath ankylosing spondylitis disease activity index; csDMARD = conventional synthetic Disease Modifying anti-Rheumatic Drugs; CRP=C-reactive protein; INF= infliximab originator; CT-P13= infliximab biosimilar; ETN= etanercept originator; SB4 etanercept biosimilar
*Comorbidities only available from Sweden, Denmark and Finland, percentage thus calculated as the proportion of patients in the whole cohort living in these countries.
**Missing data on csDMARD is due to patients missing a visit within the specified time-frame defined as baseline.